New Phase 3 Trial Data Show IVIG Improves Outcomes in Autoimmune Encephalitis
Autoimmune encephalitis is a group of immune-mediated brain disorders that can cause a frightening range of symptoms: sudden memory loss, seizures, personality changes, psychiatric disturbances, and a general decline in neurological function. In many cases, the immune system produces antibodies that mistakenly attack proteins on the surface of brain cells, disrupting normal signaling. It can affect people of any age and is often misdiagnosed as a psychiatric condition before the autoimmune nature is recognized. Early treatment is critical, and yet the evidence base for many of the therapies used has historically been limited to small or retrospective studies.
That picture shifted meaningfully in April 2026, when researchers presented phase 3 clinical trial results at the American Academy of Neurology Annual Meeting in Chicago. The double-blind, active-controlled study enrolled 40 patients who had not responded adequately to steroid pulse therapy, a standard first-line intervention. Led by Ko Sakamoto, MD, of Takeda Pharmaceutical Company, the trial randomized participants 1:1 to receive either an investigational intravenous immunoglobulin formulation called NPB-01 or continued steroid pulse therapy. The primary goal was to achieve at least a 40 percent improvement on a validated symptom scale called the Clinical Assessment Scale in Autoimmune Encephalitis, measured at four weeks.
Among patients with antibodies targeting cell-surface antigens, which represent the most clearly defined subgroup in autoimmune encephalitis, the results were striking. Response rates reached 57.1 percent in the IVIG group compared with zero percent in the control group. In the broader study population, IVIG produced a 50 percent response rate versus 25 percent with continued steroids. Secondary outcomes, including changes in the modified Rankin Scale that measures functional disability, also favored the IVIG group. Safety was reassuring: adverse events were generally mild to moderate, and the overall profile was comparable between the two arms.
IVIG is a therapy derived from pooled donor plasma that works through several mechanisms at once. It modulates autoantibodies, inhibits complement activation, and affects signaling through receptors on immune cells. Clinicians have used it for years in other neurological conditions, including Guillain-Barre syndrome, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. What has been missing until now is robust controlled trial evidence specifically in autoimmune encephalitis, where most prior data came from case series or small prospective studies.
The NPB-01 formulation studied here is a next-generation product designed to enhance anti-inflammatory activity and optimize dosing efficiency compared with conventional IVIG preparations. Researchers believe that improvements in Fc-mediated immune modulation could translate into more consistent and potent treatment effects for patients with brain-directed autoimmunity. These findings could inform how clinicians sequence treatment for patients who do not improve with first-line corticosteroids, a scenario where rapid escalation is often needed to prevent lasting neurological damage.
Important limitations remain. The sample was small at just 40 participants, and autoimmune encephalitis is a heterogeneous condition with many subtypes and varying antibody profiles. Longer follow-up and larger confirmatory studies will be needed to establish durability of response and to identify which patients are most likely to benefit. Still, for a condition where treatment decisions have so often been guided by clinical intuition rather than controlled evidence, these phase 3 results mark a meaningful step forward.